Breaking News

AstraZeneca to Build ADC Manufacturing Facility in Singapore

Will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca has announced plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs).   The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.   Pascal Soriot, CEO, AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters